CIK 0001360214
- Large accelerated filer
HARROW, INC.
Sign in to watch- Ticker
- HROW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 450567010
- Phone
- +1 615-733-4731
- Business address
- 1A BURTON HILLS BLVD, SUITE 200, NASHVILLE, TN
- Former names
- HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., TRANSDEL PHARMACEUTICALS INC, Bywater Resources, Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-07 | SAHAREK JOHN P. CEO & President, ImprimisRx | Shares withheld for taxes | −109,475 | $23.09 | $2.5M | 467,388 |
| 2025-04-03 | SAHAREK JOHN P. CEO & President, ImprimisRx | Exercise or conversion | +277,200 | 576,863 | ||
| 2025-04-03 | SAHAREK JOHN P. CEO & President, ImprimisRx | Exercise or conversion · Performance Stock Unit | −277,200 | 0 | ||
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion | +90,000 | $7.37 | $663K | 344,803 |
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Shares withheld for taxes | −45,140 | $41.37 | $1.9M | 299,663 |
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion · Stock Option (Right to Buy) | −90,000 | 0 | ||
| 2024-03-01 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion | +5,000 | $8.75 | $44K | 254,803 |
| 2024-03-01 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion · Stock Option (Right to Buy) | −5,000 | 0 | ||
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion | +30,000 | $10.67 | $320K | 262,419 |
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion | −12,616 | $10.67 | $135K | 249,803 |
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Exercise or conversion · RSU | −30,000 | 0 | ||
| 2023-11-10 | SAHAREK JOHN P. Chief Commercial Officer | Exercise or conversion | +20,000 | 242,197 | ||
| 2023-11-10 | SAHAREK JOHN P. Chief Commercial Officer | Shares withheld for taxes | −9,778 | $12.83 | $125K | 232,419 |
| 2023-11-10 | SAHAREK JOHN P. Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) | −20,000 | 0 | ||
| 2023-07-18 | SAHAREK JOHN P. Chief Commercial Officer | Exercise or conversion | +277,200 | 331,277 | ||
| 2023-07-18 | SAHAREK JOHN P. Chief Commercial Officer | Shares withheld for taxes | −109,080 | $18.23 | $2.0M | 222,197 |
| 2023-07-18 | SAHAREK JOHN P. Chief Commercial Officer | Exercise or conversion · Performance Stock Unit | −277,200 | 0 | ||
| 2023-04-03 | SAHAREK JOHN P. Chief Commercial Officer | Grant or award · Restricted Stock Unit | +277,200 | 277,200 | ||
| 2022-02-19 | SAHAREK JOHN P. President, ImprimisRx | Exercise or conversion | +50,000 | 80,000 | ||
| 2022-02-19 | SAHAREK JOHN P. President, ImprimisRx | Shares withheld for taxes | −25,923 | $7.87 | $204K | 54,077 |
Page 1 of 2 · 32 trades